3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Precancerous Conditions
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Tongue Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Brain Neoplasms
1
Bile Duct Neoplasms
1
Basal Cell Nevus Syndrome
1
Interventions
Cisplatin
27
pembrolizumab
21
Brachytherapy
16
Radiotherapy
14
Carboplatin
10
Radiation
8
Paclitaxel
8
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Topotecan
6
fludarabine
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Fluorodeoxyglucose F18
5
Cyclophosphamide
5
Bevacizumab
5
durvalumab
4
Nivolumab
4
Gemcitabine
4
tremelimumab
3
temsirolimus
3
human papillomavirus vaccine, L1 type 16, 18
3
aldesleukin
3
Radiotherapy, Intensity-Modulated
3
Papillomavirus Vaccines
3
Ipilimumab
3
Interleukin-2
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Docetaxel
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Uterine Cervical Neoplasms
×
Microarray Analysis
×
Clear all
NCT00629577
2017-02-01
SAGE
British Columbia Cancer Agency
Phase 1
Terminated
50 enrolled